Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert S. Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Elizabeth Lokich, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian

Open source

DOI: 10.1038/s41591-025-03566-1
Published: 2025-03-05
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-03566-1,
  title = {Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial},
  author = {Ramez N. Eskander and Michael W. Sill and Lindsey Beffa and Richard G. Moore and Joanie M. Hope and Fernanda B. Musa and Robert S. Mannel and Mark S. Shahin and Guilherme H. Cantuaria and Eugenia Girda and Elizabeth Lokich and Juraj Kavecansky and Charles A. Leath and Lilian T. Gien and Emily M. Hinchcliff and Shashikant B. Lele and Lisa M. Landrum and Floor Backes and Roisin E. O’Cearbhaill and Tareq Al Baghdadi and Emily K. Hill and Premal H. Thaker and Veena S. John and Stephen Welch and Amanda N. Fader and Matthew A. Powell and Carol Aghajanian},
  year = {2025},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-025-03566-1},
  url = {https://doi.org/10.1038/s41591-025-03566-1}
}

RIS

TY  - JOUR
TI  - Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
AU  - Ramez N. Eskander
AU  - Michael W. Sill
AU  - Lindsey Beffa
AU  - Richard G. Moore
AU  - Joanie M. Hope
AU  - Fernanda B. Musa
AU  - Robert S. Mannel
AU  - Mark S. Shahin
AU  - Guilherme H. Cantuaria
AU  - Eugenia Girda
AU  - Elizabeth Lokich
AU  - Juraj Kavecansky
AU  - Charles A. Leath
AU  - Lilian T. Gien
AU  - Emily M. Hinchcliff
AU  - Shashikant B. Lele
AU  - Lisa M. Landrum
AU  - Floor Backes
AU  - Roisin E. O’Cearbhaill
AU  - Tareq Al Baghdadi
AU  - Emily K. Hill
AU  - Premal H. Thaker
AU  - Veena S. John
AU  - Stephen Welch
AU  - Amanda N. Fader
AU  - Matthew A. Powell
AU  - Carol Aghajanian
PY  - 2025
JO  - Nature Medicine
DO  - 10.1038/s41591-025-03566-1
UR  - https://doi.org/10.1038/s41591-025-03566-1
ER  -

APA

Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R. S., Shahin, M. S., Cantuaria, G. H., Girda, E., Lokich, E., Kavecansky, J., Leath, C. A., Gien, L. T., Hinchcliff, E. M., Lele, S. B., Landrum, L. M., Backes, F., O’Cearbhaill, R. E., Baghdadi, T. A., Hill, E. K., Thaker, P. H., John, V. S., Welch, S., Fader, A. N., Powell, M. A., & Aghajanian, C. (2025). Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03566-1

Source records

crossref · retrieved 2026-09-26T00:53:55.741Z